Mpox

Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.

Retrieved on: 
Tuesday, April 2, 2024
Health, Advisory Committee, Disease, OMX, Partnership, Risk, Trust, Pharmacy, Public, Mpox, Infection, CDC, Vaccination, Vaccine, FDA, Government, ACIP, Pharmaceutical industry

Since 2022, in response to the global mpox outbreak, JYNNEOS has been made available through public health channels for individuals at risk of mpox infection.

Key Points: 
  • Since 2022, in response to the global mpox outbreak, JYNNEOS has been made available through public health channels for individuals at risk of mpox infection.
  • According to estimates from the CDC, two (2) million U.S. individuals are eligible for vaccination against mpox4.
  • Recent data shows 60% of this population remains completely unvaccinated, and 15% have received only one dose of the vaccine5.
  • Through its existing nationwide vaccine distribution structure, Bavarian Nordic is now making the mpox vaccine commercially available across the nation.

Morris & Dickson is the First U.S. Distributor for Bavarian Nordic’s JYNNEOS®, the Only FDA-approved Mpox Vaccine

Retrieved on: 
Wednesday, April 3, 2024
Infectious Diseases, Pharmaceutical, Health, Disease, Smallpox, Virus, Mpox, Viral disease, Infection, CDC, Bavarian Nordic, Family, FDA, Pharmaceutical industry

Morris & Dickson is proud to announce it is the first U.S. distributor of Bavarian Nordic’s newly launched mpox vaccine, JYNNEOS®.

Key Points: 
  • Morris & Dickson is proud to announce it is the first U.S. distributor of Bavarian Nordic’s newly launched mpox vaccine, JYNNEOS®.
  • As the only FDA-approved mpox vaccine, JYNNEOS is now commercially available in the U.S., marking a significant expansion for access.
  • Bavarian Nordic announced its commercial entry into the US on April 2, noting the ongoing need for the vaccine.
  • “We are proud to be a key partner in expanding access to this first-to-market vaccine,” says Layne Martin, head of Specialty at Morris & Dickson.

Global Monkeypox Diagnostics Market Research Report 2024: Market Analysis & Forecasts 2022-2026 with Executive & Consultant Guides - ResearchAndMarkets.com

Retrieved on: 
Friday, March 1, 2024
Biotechnology, Infectious Diseases, Hospitals, Health, Medical Supplies, Place, COVID-19, Mpox, Growth, Genomics

The "Global Monkeypox Diagnostics Market by Assay, Country, Product, and Place, with Executive & Consultant Guides and Market Analysis & Forecasts 2022-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Monkeypox Diagnostics Market by Assay, Country, Product, and Place, with Executive & Consultant Guides and Market Analysis & Forecasts 2022-2026" report has been added to ResearchAndMarkets.com's offering.
  • This report forecasts the market size out to 2026.
  • Growth is coming from basic factors but the COVID-19 pandemic has changed the market landscape now and for the foreseeable future.
  • The two key trends of Rapid Diagnostics and the Genomics Revolution are merging to create new diagnostic opportunities.

Global Continuing Medical Education Market Outlook Report 2023-2028 - Increasing Demand for Short-Term CME Courses

Retrieved on: 
Thursday, February 22, 2024
Diabetes, Hospital, Omnichannel, Mpox, Time management, Physician, Growth, Cancer, Prevalence, Attention, School, COVID-19, Disability, Disease, Organization, Accreditation, CME, Medicine, Knowledge, Infection, Mortality, Nursing

DUBLIN, Feb. 22, 2024 /PRNewswire/ -- The "Global Continuing Medical Education Market - Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 22, 2024 /PRNewswire/ -- The "Global Continuing Medical Education Market - Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The healthcare education market has a massive demand for physicians and other medical staff, where the supply is scarce.
  • North America is one of the leading regions in the global continuing medical education market, accounting for a higher market share.
  • In 2022, North America accounted for approximately 36% of the market share in the global continuing medical education market and dominated the other regions.

CDC awards Truveta a real-world data contract to study COVID, maternal health, and pediatric care

Retrieved on: 
Monday, January 22, 2024
Patient, Risk, Health, Policy, Natural history, COVID, Mpox, Public, Infection, CDC, Disease, COVID-19, Coronavirus, SARS-CoV-2, EHR, Vaccine

Truveta will provide real-world data for CDC researchers to conduct respiratory virus surveillance, including COVID-19, as well as data to facilitate studies on maternal health and pediatric care.

Key Points: 
  • Truveta will provide real-world data for CDC researchers to conduct respiratory virus surveillance, including COVID-19, as well as data to facilitate studies on maternal health and pediatric care.
  • Truveta Data will help facilitate the CDC's COVID response and surveillance efforts as it enables CDC scientists to access representative patient-level data, without delays, for statistically significant populations.
  • "As the coronavirus pandemic began ravaging our country and the world, Truveta was formed in 2020 to bring together data that would enable faster answers and better care,” said Truveta CEO Terry Myerson.
  • We are honored that our unique data will help the CDC advance its mission of working 24/7 to save lives and protect people."

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

Retrieved on: 
Tuesday, December 19, 2023
Mpox, HHS, Infection, Immune system, Biotechnology, NIAID, Virus, License, Vaccine, Patent, Disease, City, COH, GeoVax, COVID-19, Cancer, Smallpox, Bangladesh Technical Education Board, HIV, SARS-CoV-2, Orthopoxvirus, NIH, Immunization, MVA

The amendment expands GeoVax’s commercial license to include Mpox and smallpox as additional indications.

Key Points: 
  • The amendment expands GeoVax’s commercial license to include Mpox and smallpox as additional indications.
  • Modified Vaccinia Ankara (MVA) is the vaccine currently used and stockpiled in the U.S. Strategic National Stockpile for immunization against the Mpox and smallpox viruses.
  • The addition of the Mpox and smallpox indications to our NIAID License Agreement complements GeoVax’s license agreement with COH for GEO-CM04S1, which we also recently amended to obtain development and commercialization rights against orthopoxviruses in addition to SARS-CoV-2.
  • For those regions/populations where Mpox and/or smallpox may be of a concern, we believe our COVID-19 vaccine will be a better choice.”

BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda

Retrieved on: 
Monday, December 18, 2023
RNA, Entrepreneurship, Epidemic, Partnership, Pasteur Institute, Government, State, African, Messenger, Research, WHO, Excellency, Vaccine, Mortality, Quality control, BNTX, CEPI, Republic, Coalition, Laboratory, BioNTech, COVID-19, HIV, Tuberculosis, World Health Organization, Mpox, Infection, Child

President Paul Kagame of Rwanda, Heads of State and Government from Africa and around the world, leadership of the African Union and European Union, as well as from WHO, Africa CDC and CEPI attended the official inauguration of the BioNTech site in Kigali

Key Points: 
  • President Paul Kagame of Rwanda, Heads of State and Government from Africa and around the world, leadership of the African Union and European Union, as well as from WHO, Africa CDC and CEPI attended the official inauguration of the BioNTech site in Kigali
    KIGALI, Rwanda, December 18, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) has reached the next milestone in the establishment of mRNA vaccine manufacturing capacities in Africa with the inauguration of the Company’s site in Kigali, Rwanda.
  • The Company’s manufacturing site in Kigali could become the first commercial-scale mRNA manufacturing facility on the continent.
  • In 2024, BioNTech expects to complete all buildings on site, including a warehouse, offices and laboratories for quality control.
  • BioNTech plans to conduct clinical trials in Africa for vaccine candidates against malaria, tuberculosis and HIV in 2024.

Microbix & BioGX Collaborate on real-time PCR Assays & Controls

Retrieved on: 
Thursday, December 7, 2023
Herpes simplex, Chickenpox, Mpox, OTCQX, Collection, Business, Applied Biosystems, PCR, Syphilis, Refrigeration, COVID, Business development, SARS-CoV-2, TSX, SVP, Pleasure, XFree86, Treponema pallidum

Microbix was chosen by BioGX to be the primary External Quality Controls provider for assays on their newly-launched pixl platform – a benchtop instrument with capabilities for syndromic testing.

Key Points: 
  • Microbix was chosen by BioGX to be the primary External Quality Controls provider for assays on their newly-launched pixl platform – a benchtop instrument with capabilities for syndromic testing.
  • Microbix QAPs are now referenced in BioGX Assay Product Inserts (available at https://www.biogx.com ), with additional QAPs to be referenced as the collaboration expands.
  • Xfree technology provides a complete lyophilized test in a single tube – using the trusted BioGX Sample-Ready™ format for extraction-free, direct sample addition in real-time PCR testing.
  • Phil Casselli, SVP of Sales & Business Development at Microbix, commented, “It has been a pleasure to work with Robert and his team at BioGX to support their customer base with robust External Quality Controls.

Mpox (Monkeypox) Vaccine Triggers Equally Strong Immune Response in Smaller Than Usual Doses and in People With or Without HIV

Retrieved on: 
Thursday, December 14, 2023
World Health Organization, NYU Langone Health, Mental Hygiene, Research, National Institutes of Health, New Yorker, Coinfection, Risk, Congo, Vaccination, Infection, Death, FDA, Division, Mpox, CD4, Master of Science, NYU, HIV, CDC, Antibody, Doctor of Philosophy, Skin, Jeff Kottkamp, Injection, Face, Immunoglobulin G, Smallpox, Democratic republic, Vaccine, Pharmaceutical industry, MD

Because of limited space between skin layers, intradermal injections can only accommodate small doses, while larger doses generally require subcutaneous injections.

Key Points: 
  • Because of limited space between skin layers, intradermal injections can only accommodate small doses, while larger doses generally require subcutaneous injections.
  • The smaller doses, about one-fifth of the usual full dose and spread out by as long as three months, were designed to stretch the short supply of vaccine available after an outbreak in May 2022.
  • The IgG antibodies were detected in some cases more than six months after a second and final dose of the vaccine.
  • The mpox vaccine is now routinely recommended by the Centers for Disease Control and Prevention (CDC) for people at risk.

Tonix Pharmaceuticals’ Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

Retrieved on: 
Thursday, November 2, 2023
Monkeypox virus, FDA, National Institute of Allergy and Infectious Diseases, HHS, Food, Therapy, Vaccine, SARS-CoV-2, NIAID, Face, Mpox, Project, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Volunteering, Tonix Pharmaceuticals, Clinical trial, COVID-19, Smallpox, Nextgen, Animal, RPV, NIH, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Infection, Tuberculosis, Bangladesh Technical Education Board

CHATHAM, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), will conduct a Phase 1 clinical trial with TNX-1800 (recombinant horsepox virus, live vaccine),1 Tonix Pharmaceuticals’ vaccine candidate to protect against COVID-19.

Key Points: 
  • Tonix is developing a novel vaccine platform initially targeting COVID-19, smallpox and mpox (monkeypox).
  • The intent is to provide durable protection against severe disease and prevent forward transmission, primarily by eliciting a T-cell immune response.
  • “TNX-1800 will be the first vaccine candidate using our live virus recombinant pox virus (RPV) platform technology to enter clinical trials.
  • NIAID will be conducting clinical trials to evaluate several early-stage vaccine candidates.